We are live on
!
Find out more
ACM
Altium Capital Management Portfolio holdings
AUM
$42M
This Fund
S&P 500
This Quarter
Est. Return
-16.47%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$41.5M
AUM Growth
-$311M
(-88%)
Cap. Flow
-$295M
Cap. Flow
% of AUM
-711.77%
Top 10 Holdings %
Top 10 Hldgs %
86.71%
Holding
72
New
5
Increased
–
Reduced
17
Closed
48
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LGMK
LogicMark
LGMK
|
+$3.72M |
| 2 |
SKYA
SkyAI Inc
SKYA
|
+$3.02M |
| 3 |
Intelligent Bio Solutions
INBS
|
+$278K |
| 4 |
SBFM
Sunshine Biopharma
SBFM
|
+$127K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ADMA Biologics
ADMA
|
+$23.9M |
| 2 |
Vera Therapeutics
VERA
|
+$18.3M |
| 3 |
Sarepta Therapeutics
SRPT
|
+$15.4M |
| 4 |
Establishment Labs
ESTA
|
+$14.1M |
| 5 |
Edwards Lifesciences
EW
|
+$12.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.55% |
| 2 | Technology | 0.27% |
| 3 | Consumer Staples | 0.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Zevra Therapeutics
ZVRA
$575M
| $9.64M | 23.23% |
1,287,333
-562,667
| -30% | -$4.47M |
|
2
PUT
Alnylam Pharmaceuticals
ALNY
$38.5B
| $6.75M | 16.27% |
+25,000
| New | +$6.42M |
|
3
Evolus
EOLS
$410M
| $3.56M | 8.59% |
296,193
-388,807
| -57% | -$5.08M |
|
4
Xtant Medical Holdings
XTNT
$59.7M
| $3.41M | 8.21% |
7,252,998
-162,415
| -2% | -$85.5K |
|
|
AVDL
5
DELISTED
Avadel Pharmaceuticals
AVDL
| $3.28M | 7.91% |
419,131
-33,344
| -7% | -$279K |
|
|
CTNM
6
Contineum Therapeutics
CTNM
$529M
| $2.12M | 5.11% |
303,857
-30,143
| -9% | -$274K |
|
|
PROF
7
Profound Medical
PROF
$263M
| $2.1M | 5.06% |
360,589
-124,411
| -26% | -$859K |
|
8
Xenon Pharmaceuticals
XENE
$6.28B
| $2.02M | 4.87% |
60,251
-227,749
| -79% | -$8.65M |
|
|
EPIX
9
DELISTED
ESSA Pharma
EPIX
| $1.66M | 4% |
1,050,369
-377,631
| -26% | -$639K |
|
10
Skye Bioscience
SKYE
$21.6M
| $1.44M | 3.47% |
904,865
-234,135
| -21% | -$639K |
|
|
ACOG
11
Alpha Cognition
ACOG
$183M
| $898K | 2.16% |
177,416
-97,584
| -35% | -$570K |
|
12
Rezolute
RZLT
$474M
| $881K | 2.12% |
303,949
-1,390,051
| -82% | -$6.05M |
|
13
Nektar Therapeutics
NKTR
$2.39B
| $715K | 1.72% |
70,092
-129,908
| -65% | -$1.7M |
|
|
AVR
14
Anteris Technologies
AVR
$795M
| $614K | 1.48% |
168,589
-568,411
| -77% | -$3.65M |
|
15
Larimar Therapeutics
LRMR
$398M
| $587K | 1.42% |
273,204
-231,796
| -46% | -$733K |
|
16
ProMIS Neurosciences
PMN
$130M
| $399K | 0.96% |
22,970
-286
| -1% | -$6.07K |
|
|
NVNO
17
enVVeno Medical
NVNO
$6.94M
| $324K | 0.78% |
3,522
-5,335
| -60% | -$594K |
|
|
18
CALL
Xenon Pharmaceuticals
XENE
$6.28B
| $315K | 0.76% |
9,400
| – | – |
|
|
19
Intelligent Bio Solutions
INBS
$3.8M
| $215K | 0.52% |
+14,925
| New | +$278K |
|
20
Karyopharm Therapeutics
KPTI
$161M
| $185K | 0.44% |
49,333
| – | – |
|
|
SKYA
21
SkyAI Inc
SKYA
$59.3M
| $110K | 0.27% |
+13,480
| New | +$3.02M |
|
|
LGMK
22
DELISTED
LogicMark
LGMK
| $107K | 0.26% |
+5,395,308
| New | +$3.72M |
|
|
SBFM
23
Sunshine Biopharma
SBFM
$3.04M
| $96.4K | 0.23% |
+5,047
| New | +$127K |
|
|
SRXH
24
SRX Global
SRXH
$28.9M
| $67.1K | 0.16% |
877
-1,788
| -67% | -$152K |
|
|
25
ADMA Biologics
ADMA
$2.04B
| – | – |
-1,395,000
| Closed | -$23.9M |
|
Similar funds
TA
SIM
LSA
VEPM
GC
VI
BCM
VAM
Altium Capital Management's Q1 2025 Portfolio in Review
As of Q1 2025, Altium Capital Management held 72 positions worth $41.5M, down 88% from $353M the previous quarter. Its ten largest holdings account for 87% of the portfolio.
Altium Capital Management withdrew a net $295M in Q1 2025, closing 48 positions and reducing 17 holdings. Its most notable exit was ADMA Biologics, an estimated $23.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, down from 91% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Altium Capital Management opened a new position in LogicMark worth $107K.
- Altium Capital Management's largest Q1 2025 buy was LogicMark: 5,395,308 shares worth $107K.
- Altium Capital Management's biggest Q1 2025 reduction was Xenon Pharmaceuticals, cutting an estimated $8.65M.
- Altium Capital Management fully exited ADMA Biologics in Q1 2025, selling an estimated $23.9M.
- Altium Capital Management's ten largest holdings make up 87% of its $41.5M portfolio in Q1 2025.
- Altium Capital Management opened 5 new positions and closed 48 in Q1 2025.
- Altium Capital Management's portfolio value fell 88% quarter-over-quarter to $41.5M.
Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.